|
$ millions |
% change from 2007 |
Revenues |
15,003.0 |
1.6 |
Profits |
4,196.0 |
32.5 |
Assets |
36,443.0 |
— |
Stockholders' equity |
20,386.0 |
— |
Market value (3/27/2009) |
53,404.2 |
— |
Profits as % of |
|
Revenues |
28.0 |
Assets |
11.5 |
Stockholders' equity |
20.6 |
Earnings per share |
|
2008 $ |
3.90 |
% change from 2007 |
38.3 |
1998-2008 annual growth rate % |
16.9 |
Total return to investors |
% |
2008 |
24.4 |
1998-2008 annual rate |
8.2 |
4 | Merck | 103 | 23,850.3 | 5 | Wyeth | 110 | 22,833.9 | 6 | Bristol-Myers Squibb | 120 | 21,366.0 | 7 | Eli Lilly | 122 | 20,378.0 | 8 | Schering-Plough | 138 | 18,502.0 | 9 | Amgen | 168 | 15,003.0 | 10 | Gilead Sciences | 444 | 5,335.8 | 11 | Mylan | 462 | 5,137.6 | 12 | Genzyme | 502 | 4,605.0 | 13 | Allergan | 517 | 4,403.4 | 14 | Biogen Idec | 546 | 4,097.5 | 15 | Forest Laboratories | 569 | 3,836.3 | 16 | Hospira | 597 | 3,629.5 | 17 | Watson Pharmaceuticals | 769 | 2,535.5 | 18 | Celgene | 830 | 2,254.8 | 19 | NBTY | 852 | 2,179.5 | 20 | Cephalon | 903 | 1,974.6 | 21 | Perrigo | 958 | 1,822.1 |
|
See Amgen in...
...Featured Companies
(1 of 1)
|